Abstract 497P
Background
Immune checkpoint inhibitors (ICIs) has been shown to be effective and has become the standard of care as first-line treatment of advanced NSCLC. Multiple previous studies of tumors have allowed the continued use of anti-PD-1 antibody therapy after first-line treatment progress. Subgroup analyses of these studies showed that 13-33% of patients receiving anti-PD-1 antibody therapy after progress achieved partial response (PR). The combination of ICIs and anti-angiogenic therapy has a synergistic anti-tumor effect and can improve the prognosis of patients. This study was designed to evaluate the efficacy and safety of sintilimab in combination with anlotinib in NSCLC disease progressed after first-line treatment with anti-PD-1 antibody.
Methods
An open, single-arm, phase II trial was designed, which enrolls NSCLC patients with disease progression after first-line treatment with anti-PD-1 antibody. Sintilimab (200 mg, day 1) in combination with anlotinib (12mg, day 1 to 14) were given every 3 weeks. Primary end point is objective response rate (ORR) evaluated via RECIST 1.1. Key secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety (CTCAE 5.0).
Results
From 3/2021 to 6/2023, 17 patients were enrolled. The median age was 63 years old (range 45-73) and 100% (17/17) was male. In 14 patients with efficacy data, 14.3% (2/14) achieved partial response (PR) and 71.4% (10/14) achieved stable disease (SD). ORR and DCR were 14.3% (and 85.7%, respectively. Until the last follow-up, the median PFS was 6.0 months(95% CI, range 4.2-7.7 months), 6-month PFS rate was 56.4%. The median OS was 17.9 months(95% CI, range 5.6-NA months), 12-month OS rate was 64.6%. Grade 3/4 treatment-related adverse events (TRAEs) included: hand and foot skin reaction (5.9%, 1/17), increased alanine aminotransferase (5.9%, 1/17), hypertension (11.8%, 2/17), hypertriglyceridemia (5.9%, 1/17) and neutropenia (5.9%, 1/17). No treatment-related deaths occurred.
Conclusions
Given the encouraging anti-tumor activity and favorable tolerability, the combination of sintilimab and anlotinib could be an effective and safe option for NSCLC.
Clinical trial identification
Clinical trial information: NCT04691388.
Editorial acknowledgement
Legal entity responsible for the study
Xinmin Yu.
Funding
1. Innovent Biologics, Inc. 2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract